A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy.

Trial Profile

A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Ramucirumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms REVEL
  • Sponsors Eli Lilly
  • Most Recent Events

    • 18 Oct 2017 Results of subgroup analysis reporting outcomes from patients who participated in REVEL according to their time to tumor progression (TTP) on first line therapy presented at the 18th World Conference on Lung Cancer
    • 18 Oct 2017 Results of post-hoc analysis assessing neutropenia, clinical consequences and quality of life presented at the 18th World Conference on Lung Cancer
    • 16 Oct 2017 Results from a subgroup analysis presented in an Eli Lilly media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top